



**PHARMACY AND THERAPEUTICS COMMITTEE
MEDICARE MEETING MINUTES
PPO-POS, HMO-POS, HMO-SNP
August 27, 2026**

Attendance:

Microsoft Teams Meeting

Rojin Baniyadi, Pharmacy Resident; Kelly Bartolone, Staff/Clinical Pharmacist; Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Lauren Grantz, Administrator Outpatient Pharmacy Services, Jefferson Enterprise; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Samantha Jackson, Formulary Pharmacist; Ruth John, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Derek McFerran, Vice President, Pharmacy Operations; Michele McKenna, Staff/Clinical Pharmacist; Janvi Morker, Pharmacy Student Intern; Lisa Murray, Staff/Clinical Pharmacist; Saad Nayyer, Pharmacy Student Intern; Jennifer Nguyen, Pharmacy Student Intern; Claudia Pinketti, Staff/Clinical Pharmacist; Ryan Prager, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovec, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Michelle Tran, Pharmacy Resident; Fallan Vaisberg, Formulary Pharmacist; Reena Varghese, Staff/Clinical Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused:

Dr. Paul Aitken, Medical Director; Jerry Crawford, Staff/Clinical Pharmacist; Kristen DeSorte, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Hailey Fry, Centennial Pharmacy; Dr. Merleen Harris-Williams, Medical Director; Jessica Hoang-Le, Staff/Clinical Pharmacist; Sheenu Joseph, Staff/Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Tara Swartz, Staff/Clinical Pharmacist

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the May 2026 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>	
<i>Welcome</i>	<i>D. Dolores introduced the new VP of Pharmacy, Derek McFerran, and our new residents Michelle Tran and Rojin Baniasadi</i>		<i>D. Dolores</i>	<i>Informational</i>	
<i>CMS Program Audit</i>	<i>H. McCaffrey and D. Dolores provided an update on the CMS program audit</i>		<i>H. McCaffrey D. Dolores</i>	<i>Informational</i>	
<i>Bridge Program Update</i>	<i>H. McCaffrey provided an update on the Bridge Program</i>		<i>H. McCaffrey</i>	<i>Informational</i>	

II. Drug Formulary Review/Update

TOPIC	DISCUSSION			ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
2027 Prior Authorization Criteria – CMS Review	<i>The Committee reviewed the 2027 Prior Authorization Criteria CMS review. The Committee approved as presented:</i>			<i>The Committee approved the 2027 Prior Authorization Criteria CMS Review. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>	
	Category	Criteria Name	Formulary Status (6T Premium, 5T Core, 5T Value)				
	<i>IgA nephropathy (IgAN)</i>	<i>Filspari</i>	<i>T5, PA, QL: 200 mg: 30/30 days, 400 mg 60/30 days</i>				
		<i>Tarpeyo</i>	<i>T5, PA, QL: 120/30 days</i>				
	<i>Colony Stimulating Factors</i>	<i>Leukine</i>	<i>T5, PA</i>				
	<i>Amyloid-Targeted mAbs, Alzheimer's</i>	<i>Leqembi Iqlik</i>	<i>T5, PA, QL: 7.2/28 days</i>				
	<i>Phosphate Binders</i>	<i>Phosphate Binders - Calcium acetate</i>	<i>T3, PA</i>				
		<i>Phosphate Binders - Sevelamer</i>	<i>T4, PA</i>				
	<i>Monoclonal Antibody, Respiratory</i>	<i>Nucala</i>	<i>T5, PA, QL: 100 mg 3/28 days, 40 mg 0.4/28 days</i>				
	<i>Liver Disease</i>	<i>Rezdiffra</i>	<i>T5, PA, QL: 30/30 days</i>				
	<i>Inhaled Antibiotics</i>	<i>Tobi Podhaler</i>	<i>T5, PA, QL: 224/56 days</i>				
	<i>Pulmonary Hypertension</i>	<i>Macitentan</i>	<i>T5, PA, QL: 30/30 days</i>				
	<i>Tuberculosis Agents</i>	<i>Pretomanid</i>	<i>T4, PA, QL: 30/30 days</i>				

TOPIC	DISCUSSION				ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING	DUE DATE
	Immunologic Agents	Entyvio	T5, PA, QL 1.36/28 days					
		Tofacitinib	T5, PA, QL: IR tablet 60/30 days, XR tablet 30/30 days, solution 480/24 days					
		Zeposia	T5, PA, QL: 30/30 days					
2027 Step Therapy Criteria CMS Review	The Committee reviewed the 2027 Step Therapy Criteria CMS Review. The Committee approved as presented:				The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved	
	Criteria Name	6T Premium (HMO-SNP)	5T Core (HMO)	5T Value (PPO, HMO)				
	Brand Antipsychotics ST NSO	X						
	SGLT2 Inhibitors ST NSO	X						

III. 2027 Formulary Changes

2027 Formulary Additions – CMS Review	The Committee reviewed the 2027 Formulary Additions CMS Review. The Committee approved as presented:				The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved	
	Drug Name	6T Premium (HMO-SNP)	5T Core (HMO)	5T Value (PPO, HMO)				
	Breyna 80-4.5 mcg/act, 160-4.5 mcg/act	T4, QL: 10.3/30 days	T4, QL: 10.3/30 days	T4, QL: 10.3/30 days				
	Budesonide-formoterol 80-4.5 mcg/act, 160-4.5 mcg/act	T4, QL 10.2/30 days	T4, QL 10.2/30 days	T4, QL 10.2/30 days				
	Erythromycin ethylsuccinate suspension	T4	T4	T4				
	Filspari 200 mg tablet	T5, PA, QL: 30/30 days	T5, PA, QL: 30/30 days	T5, PA, QL: 30/30 days				
	Filspari 400 mg tablet	T5, PA, QL: 60/30 days	T5, PA, QL: 60/30 days	T5, PA, QL: 60/30 days				
	Tarpeyo 4 mg DR capsule	T5, PA, QL: 120/30 days	T5, PA, QL: 120/30 days	T5, PA, QL: 120/30 days				
	Leqembi Iqlik 360 mg/1.8mL autoinjector	T5, PA, QL: 7.2/28 days	T5, PA, QL: 7.2/28 days	T5, PA, QL: 7.2/28 days				
	Leukine 250 mcg solution	T5, PA	T5, PA	T5, PA				

	<i>Nucala 100 mg solution</i>	<i>T5, PA, QL: 3/28 days</i>	<i>T5, PA, QL: 3/28 days</i>	<i>T5, PA, QL: 3/28 days</i>				
	<i>Nucala 100 mg/mL autoinjector</i>	<i>T5, PA, QL: 3/28 days</i>	<i>T5, PA, QL: 3/28 days</i>	<i>T5, PA, QL: 3/28 days</i>				
	<i>Nucala 40 mg/0.4mL, 100 mg/mL PFS</i>	<i>T5, PA, QL: 0.4/28 days</i>	<i>T5, PA, QL: 0.4/28 days</i>	<i>T5, PA, QL: 0.4/28 days</i>				
	<i>Pretomanid 200 mg tablet</i>	<i>T4, PA, QL: 30/30 days</i>	<i>T4, PA, QL: 30/30 days</i>	<i>T4, PA, QL: 30/30 days</i>				
	<i>Rivaroxaban 2.5 mg tablet</i>	<i>T3, QL: 60/30 days</i>	<i>T3, QL: 60/30 days</i>	<i>T3, QL: 60/30 days</i>				
	<i>Sevelamer carbonate 800 mg tablet</i>	<i>T4, PA</i>	<i>T4, PA</i>	<i>T4, PA</i>				
	<i>Calcium acetate 667 mg capsule, tablet</i>	<i>T3, PA</i>	<i>T3, PA</i>	<i>T3, PA</i>				
	<i>Bismuth/metronidazole/tetracycline capsule</i>	<i>T3</i>	<i>T3</i>	<i>T3</i>				
	<i>Rezdiffra 60 mg, 80 mg, 100 mg tablet</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>				
	<i>Tobi Podhaler 28 mg capsule</i>	<i>T5, PA, QL: 224/56 days</i>	<i>T5, PA, QL: 224/56 days</i>	<i>T5, PA, QL: 224/56 days</i>				
	<i>Entyvio pen 108 mg/0.68mL autoinjector</i>	<i>T5, PA, QL: 1.36/28 days</i>	<i>T5, PA, QL: 1.36/28 days</i>	<i>T5, PA, QL: 1.36/28 days</i>				
	<i>Zeposia 7-day Starter Pack 4 x 0.23mg & 3 x 0.46mg</i>	<i>T5, PA, QL: 7/180 days</i>	<i>T5, PA, QL: 7/180 days</i>	<i>T5, PA, QL: 7/180 days</i>				
	<i>Zeposia Starter Kit 0.23mg & 0.46mg 0.92mg</i>	<i>T5, PA, QL: 28/180 days</i>	<i>T5, PA, QL: 28/180 days</i>	<i>T5, PA, QL: 28/180 days</i>				
	<i>Zeposia 0.92 mg capsule</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>				
2027 Formulary Additions – Summer Limited Window	<i>The Committee reviewed the 2027 Formulary Additions – Summer Limited Window. The Committee approved as presented:</i>				<i>The Committee reviewed. It will be sent to CMS for approval. (See</i>	<i>S. Jackson</i>	<i>Resolved</i>	
	Drug Name	6T Premium (HMO-SNP)	5T Core (HMO)	5T Value (PPO, HMO)				

	<i>Breztri Aerosphere 160-18-4.8 mcg/act</i>	<i>T5, PA, QL: 10.7 days</i>	<i>T5, PA, QL: 10.7 days</i>	<i>T5, PA, QL: 10.7 days</i>	<i>attached for voting detail)</i>			
	<i>Ipratropium bromide HFA 17 mcg/act</i>	<i>T3, QL: 25.8/days</i>	<i>T3, QL: 25.8/days</i>	<i>T3, QL: 25.8/days</i>				
	<i>Idvynso 100-0.25 mg tablet</i>	<i>T5, QL: 30/30 days</i>	<i>T5, QL: 30/30 days</i>	<i>T5, QL: 30/30 days</i>				
	<i>Rilpivirine hcl 25 mg tablet</i>	<i>T4, QL: 30/30 days</i>	<i>T4, QL: 30/30 days</i>	<i>T4, QL: 30/30 days</i>				
	<i>Bosutinib 400 mg tablet</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>				
	<i>Jakafi 11 mg, 22 mg, 33 mg, 44 mg, 55 mg XR tablet</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>				
	<i>Lifyorli 125 dose</i>	<i>T5, PA, QL: 18/28 days</i>	<i>T5, PA, QL: 18/28 days</i>	<i>T5, PA, QL: 18/28 days</i>				
	<i>Lifyorli 150 mg dose</i>	<i>T5, PA, QL: 27/28 days</i>	<i>T5, PA, QL: 27/28 days</i>	<i>T5, PA, QL: 27/28 days</i>				
	<i>Macitentan 10 mg tablet</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>				
	<i>Relgaabi 300 mg capsule</i>	<i>T2, QL: 360/30 days</i>	<i>T2, QL: 360/30 days</i>	<i>T2, QL: 360/30 days</i>				
	<i>Relgaabi 400 mg capsule</i>	<i>T2, QL: 270/30 days</i>	<i>T2, QL: 270/30 days</i>	<i>T2, QL: 270/30 days</i>				
	<i>Sitagliptin metformin 50-500 mg, 50-1000 mg tablet</i>	<i>T2, QL: 60/30 days</i>	<i>T2, QL: 60/30 days</i>	<i>T2, QL: 60/30 days</i>				
	<i>Sitagliptin phosphate 25 mg, 50mg, 100 mg tablet</i>	<i>T6, QL: 30/30 days</i>	<i>T1, QL: 30/30 days</i>	<i>T1, QL: 30/30 days</i>				
	<i>Tofacitinib citrate 1 mg/mL solution</i>	<i>T5, PA, QL: 480/24 days</i>	<i>T5, PA, QL: 480/24 days</i>	<i>T5, PA, QL: 480/24 days</i>				
	<i>Tofacitinib citrate 5mg, 10 mg tablet</i>	<i>T5, PA, QL: 60/30 days</i>	<i>T5, PA, QL: 60/30 days</i>	<i>T5, PA, QL: 60/30 days</i>				
	<i>Tofacitinib citrate 11 mg, 22 ER mg tablet</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>	<i>T5, PA, QL: 30/30 days</i>				
2027 Formulary Removals	<i>The Committee reviewed the 2027 Formulary Removals. The Committee approved as presented:</i> <i>Atrovent HFA 17 mcg/act* - Brand removal</i>				<i>The Committee reviewed. It will be sent to CMS for</i>	<i>S. Jackson</i>	<i>Resolved</i>	

	- Bosulif 400 mg tablet* - Brand removal - Edurant 25 mg tablet* - Brand removal - Impavido 50 mg capsule - Discontinued - Janumet 50-500 mg, 50-1000 mg tablet* - Brand removal - Januvia 25 mg, 50 mg, 100 mg tablet* - Brand removal - Lutera 0.1-20 mg-mcg tablet - Discontinued - Memantine hcl 28 x 5 mg & 21 x 10 mg tablet - Discontinued - Opsumit 10 mg tablet* - Brand removal - Pacerone 400 mg tablet - Discontinued - Rybelsus 3 mg, 7 mg, 14 mg tablet - Discontinued - Vizimpro 15 mg, 30 mg, 45 mg tablet – Discontinued <i>*Brand to be removed, generic to be added.</i>	approval. (See attached for voting detail)						
2027 Quantity Limit Updates	The Committee reviewed the 2027 Quantity Limit Updates. The Committee approved as presented. Sacubitril-valsartan 24-26 mg tablet - 180/30 days	The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved				
2027 Tier Changes – CMS Review	The Committee reviewed the 2027 Tier Changes. The Committee approved as presented.				The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved	
	Drug Name	6T Premium (HMO-SNP)	5T Core (HMO)	5T Value (PPO, HMO)				
	Daptomycin 350 mg, 500 mg solution	T5 to T3						
	Dihydroergotamine mesylate 4 mg/mL solution	T5 to T3						
	Maraviroc 150 mg, 300 mg tablet	T5 to T3						
	Mesna 400 mg tablet	T5 to T3						
	Octagam 1 gm/20mL solution	T5 to T3						
	Simlandi (2 syringe) 20 mg/0.2mL PFS	T5 to T3						
	Voriconazole 200 mg solution	T5 to T3						
	Xifaxan 200 mg, 550 mg tablet	T5 to T3						

2027 Quantity Limit Additions	<i>The Committee reviewed the 2027 Quantity Limit Additions. The Committee approved as presented.</i> • <i>Bosutinib 400 mg tablet - 30/30 days</i> • <i>Breynda 80-4.5 mcg/act, 160-4.5 mcg/act - 10.3/30 days</i> • <i>Breztri Aerosphere 160-18-4.8 mcg/act - 10.7/30 days</i> • <i>Budesonide-formoterol 80-4.5 mcg/act, 160-4.5 mcg/act - 10.2/30 days</i> • <i>Entyvio pen 108 mg/0.68mL autoinjector - 1.36/28 days</i> • <i>Filspari 200 mg tablet - 30/30 days</i> • <i>Filspari 400 mg tablet - 60/30 days</i> • <i>Idvynso 100-0.25 mg tablet - 30/30 days</i> • <i>Ipratropium bromide HFA 17 mcg/act - 25.8/30 days</i> • <i>Jakafi 11 mg, 22 mg, 33 mg, 44 mg, 55 mg XR tablet - 30/30 days</i> • <i>Leqembi Iqlik 360 mg/1.8mL autoinjector - 7.2/28 days</i> • <i>Lifyorli 125 mg dose - 18/28 days</i> • <i>Lifyorli 150 mg dose - 27/28 days</i> • <i>Macitentan 10 mg tablet - 30/30 days</i> • <i>Nucala 100 mg solution - 3/28 days</i> • <i>Nucala 100 mg/mL autoinjector - 3/28 days</i> • <i>Nucala 100 mg/mL PFS - 3/28 days</i> • <i>Nucala 40 mg/0.4mL PFS - 0.4/28 days</i> • <i>Pretomanid 200 mg tablet - 30/30 days</i> • <i>Relgaabi 300 mg capsule - 360/30 days</i> • <i>Relgaabi 400 mg capsule - 270/30 days</i> • <i>Rezdifra 60 mg, 80 mg, 100 mg tablet - 30/30 days</i> • <i>Rilpivirine hcl 25 mg tablet - 30/30 days</i> • <i>Rivaroxaban 2.5 mg tablet - 60/30 days</i> • <i>Sitagliptin phos-metformin 50-500 mg, 50-1000 mg tablet - 60/30 days</i> • <i>Sitagliptin phosphate 25 mg, 50mg, 100 mg tablet - 30/30 days</i> • <i>Tarpeyo 4 mg DR capsule - 120/30 days</i> • <i>Tobi Podhaler 28 mg capsule - 224/56 days</i> • <i>Tofacitinib citrate 1 mg/mL solution - 480/24 days</i> • <i>Tofacitinib citrate 11 mg, 22 ER mg tablet - 30/30 days</i> • <i>Tofacitinib citrate 5mg, 10 mg tablet - 60/30 days</i> • <i>Zeposia 0.92 mg capsule - 30/30 days</i> • <i>Zeposia 7-day Starter Pack 4 x 0.23mg & 3 x 0.46mg - 7/180 days</i> • <i>Zeposia Starter Kit 0.23mg & 0.46mg 0.92mg - 28/180 days</i>	<i>The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)</i>	<i>S. Jackson</i>	<i>Resolved</i>	
--------------------------------------	---	--	-------------------	-----------------	--

IV. 2026 Review/Updates

2026 Prior Authorization Criteria Updates	<i>The Committee reviewed the 2026 Prior Authorization Criteria Updates. The Committee approved as presented.</i> • <i>Brand Major Depressive Disorder Agents NSO</i> • <i>Dupixent</i>	<i>The Committee reviewed. It will be sent to CMS for approval. (See</i>	<i>S. Jackson</i>	<i>Resolved</i>	
--	---	--	-------------------	-----------------	--

	Fasenra	attached for voting detail)						
2026 Formulary Additions	The Committee reviewed the 2026 Formulary Additions. The Committee approved as presented. - Auvelity Titration Pack 30-105 mg & 45-105 mg - T5, PA, QL 102/365 days - Bysanti 1, 2, 4, 6, 8, 10, 12 mg tablet - T5, ST, QL 60/30 days - Bysanti Titration Pack A 1 & 2 & 4 & 6 mg tablet - T4, ST, QL 16/365 days - Bysanti Titration Pack B 1 & 2 & 6 & 8 mg tablet - T4, ST, QL 24/365 days - Bysanti Titration Pack C 1 & 2 & 6 mg tablet - T4, ST, QL 16/365 days - Cyclosporine (PF) 0.05% emulsion - T3, QL 60/30 days - Icosapent ethyl 0.5 gm capsule - T3 - Lubiprostone 8 mcg, 24 mcg capsule* - T3, QL 60/30 days - Skyrizi 55 mg/0.37 mL PFS - T5, PA *Currently formulary for 5T Core and 6T DSNP	The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved				
2026 FRF Formulary Additions - Protected Class	The Committee reviewed the 2026 FRF Formulary Additions Protected Class. The Committee approved as presented. - Bosutinib 400 mg tablet - T5, PA, QL - Fanapt Titration Pack B 1 & 2 & 6 & 8 mg tablet - T4, ST, QL - Fanapt Titration Pack C 1 & 2 & 6 mg tablet - T4, ST, QL - Idvynso 100-0.25 mg tablet - T5, QL - Jakafi XR 11 mg, 22 mg, 33 mg, 44 mg, 55 mg tablet - T5, PA, QL - Komzifti 200 mg capsule - T5, PA, QL - Lifyorli 125 mg dose pack - T5, PA - Lifyorli 150 mg dose pack - T5, PA - Rilpivirine hcl 25 mg tablet - T5, QL	The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved				
2026 FRF Formulary Additions – Non-Protected Class	The Committee reviewed the 2026 FRF Formulary Additions Non-Protected Class. The Committee approved as presented.				The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved	
	Drug Name	6T Premium (HMO-SNP)	5T Core (PPO, HMO)	5T Value (PPO, HMO)				
	Bimatoprost 0.01% solution	T3						
	Breztri Aerosphere 160-18-4.8 mcg/act	T3, QL 10.7/30 days						
	Clopidogrel bisulfate 300 mg tablet	T2						
	Dapagliflozin-metformin 5-500 mg ER tablet	T2, QL 60/30 days						
	Dapagliflozin-metformin 10-500 mg ER tablet	T2, QL 30/30 days						

	Macitentan 10 mg tablet	T5, PA, QL 30/30 days						
	Nintedanib esylate 100 mg, 150 mg capsule	T5, PA, QL 60/30 days						
	Ozempic 1.5 mg, 4 mg, 9 mg tablet	T3, PA, QL 30/30 days						
	Relgaabi 300 mg capsule	T2, QL 360/30 days						
	Relgaabi 400 mg capsule	T2, QL 270/30 days						
	Sitagliptin phos-metformin 50-500 mg, 50-1000 mg tablet	T2, QL 60/30 days	T2, QL 60/30 days	T2, QL 60/30 days				
	Sitagliptin phosphate 25 mg, 50 mg, 100 mg tablet	T6, QL 30/30 days	T1, QL 30/30 days	T1, QL 30/30 days				
	Tofacitinib citrate 1 mg/mL solution	T5, PA, QL 480/24 days						
	Tofacitinib citrate 11 mg, 22 ER mg tablet	T5, PA, QL 30/30 days						
	Tofacitinib citrate 5mg, 10 mg tablet	T5, PA, QL 60/30 days						
	Zelvysia 100 mg packet	T5, PA						
2026 FRF Formulary Removals	The Committee reviewed the 2026 FRF Formulary Removals. The Committee approved as presented. - Boostrix 5-2.5-18.5 lf-mcg/0.5 mL suspension - Bosulif 400 mg tablet* - Impavido 50 mg capsule - Kaletra 400-100 mg/5mL solution - Kisqali Femara 400 mg, 600 mg dose pack - Lutera 0.1-20 mg-mcg tablet - Memantine hcl 28 x 5 mg & 21 x 10 mg tablet - Norvir 100 mg packet - Opsumit 10 mg tablet* - Pacerone 400 mg tablet - Rybelsus 3 mg, 7 mg, 14 mg tablet - Typhim Vi 25 mcg/0.5mL solution - Vizimpro 15 mg, 30 mg, 45 mg tablet - YF-Vax suspension These drugs will remain on the formulary until the end of the benefit year unless otherwise noted. *Brand to be removed, generic to be added.				The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)	S. Jackson	Resolved	
2026 Quantity Limit Additions	The Committee reviewed the 2026 Quantity Limit Additions. The Committee approved as presented. - Auvelity Titration Pack 30-105 mg & 45-105 mg - 102/365 days - Bosutinib 400 mg tablet - 30/30 days				The Committee reviewed. It will be sent to CMS for approval. (See	S. Jackson	Resolved	

	• <i>Breztri Aerosphere 160-18-4.8 mcg/act - 10.7/30 days</i> • <i>Bysanti 1, 2, 4, 6, 8, 10, 12 mg tablet - 60/30 days</i> • <i>Bysanti Titration Pack A 1 & 2 & 4 & 6 mg tablet - 16/365 days</i> • <i>Bysanti Titration Pack B 1 & 2 & 6 & 8 mg tablet - 24/365 days</i> • <i>Bysanti Titration Pack C 1 & 2 & 6 mg tablet - 16/365 days</i> • <i>Dapagliflozin-metformin 5-500 mg ER tablet - 60/30 days</i> • <i>Dapagliflozin-metformin 10-500 mg ER tablet - 30/30 days</i> • <i>Fanapt Titration Pack B 1 & 2 & 6 & 8 mg tablet - 24/365 days</i> • <i>Fanapt Titration Pack C 1 & 2 & 6 mg tablet - 16/365 days</i> • <i>Idvynso 100-0.25 mg tablet - 30/30 days</i> • <i>Jakafi XR 11 mg, 22 mg, 33 mg, 44 mg, 55 mg tablet - 30/30 days</i> • <i>Komzifti 200 mg capsule - 90/30 days</i> • <i>Macitentan 10 mg tablet - 30/30 days</i> • <i>Nintedanib esylate 100 mg, 150 mg capsule - 60/30 days</i> • <i>Ozempic 1.5 mg, 4 mg, 9 mg tablet - 30/30 days</i> • <i>Relgaabi 300 mg capsule - 360/30 days</i> • <i>Relgaabi 400 mg capsule - 270/30 days</i> • <i>Rilpivirine hcl 25 mg tablet - 30/30 days</i> • <i>Sitagliptin phos-metformin 50-500 mg, 50-1000 mg tablet - 60/30 days</i> • <i>Sitagliptin phosphate 25 mg, 50 mg, 100 mg tablet - 30/30 days</i> • <i>Tofacitinib citrate 1 mg/mL solution - 480/24 days</i> • <i>Tofacitinib citrate 11 mg, 22 ER mg tablet - 30/30 days</i> • <i>Tofacitinib citrate 5mg, 10 mg tablet - 60/30 days</i>	attached for voting detail)			
V. New Drug Review	The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations: • <i>Jideytro (zidesamtinib) Tablets*</i> • <i>Retevmo (selpercatinib) Capsules and Tablets</i> • <i>Revtorpyk (gedatolisib) Lyophilized Powder for Injection*</i> • <i>Keytruda (pembrolizumab) Injection</i> • <i>Padcev (enfortumab vedotin-ejfv) Lyophilized Powder for Injection</i> • <i>Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection*</i> • <i>Truxima (rituximab-abbs) Injection</i> • <i>Ibrance (palbociclib) Capsules and Tablets</i> • <i>Trodelyv (sacituzumab govitecan-hziy) Injection</i> • <i>Tecelra (afamitresgene autoleucel) Suspension for Intravenous Infusion</i> • <i>Truqap (capivasertib) Tablets</i> • <i>Cavhanza (nilotinib) Orally Disintegrating Tablets*</i> • <i>Imfinzi (durvalumab) Injection</i> • <i>Decnupaz (pivekimab sunirine-pvzy) Lyophilized Cake for Injection*</i> • <i>Datroway (datopotamab deruxitecan-dlnk) Lyophilized Powder for Injection</i>	Per CMS regulations, "The P&T committee will make a reasonable effort to review a new FDA approved drug product (or new FDA approved indication) within 90 days of its release onto the market and will make a decision on each new FDA approved drug product (or new FDA approved indication) within 180 days of its release onto the market, or a clinical justification will be	R. Baniasadi M. Tran	Resolved	

	• <i>Tecentriq (atezolizumab) Injection</i> • <i>Enhertu (fam-trastuzumab deruxtecan-nxki) Injection</i> • <i>Inqovi (decitabine and cedazuridine) Tablets</i> • <i>Beqalzi (sonrotoclast) Tablets*</i> • <i>Bizengri (zenocutuzumab-zbco) Injection</i> • <i>Veppanu (vepedegestrant) Tablets*</i> • <i>Caplyta (lumateperone) Capsules</i> • <i>Idvynso (doravirine and islatravir) Tablets*</i> <i>The following medications are Formulary with new FDA-approved indications:</i> • <i>Skyrizi (risankizumab-rzaa) Injection</i> • <i>Besremi (ropeginterferon alfa-2b-njft) Injection</i> • <i>Xeomin (incobotulinumtoxinA) Injection</i> • <i>Capvaxive (pneumococcal 21-valent conjugate vaccine) Injection</i> • <i>Tremfya (guselkumab) Injection</i> • <i>Linzess (linaclotide) Capsules</i> • <i>Fasenra (benralizumab) Injection</i> • <i>Jakafi (ruxolitinib) Tablets</i> • <i>Auvelity (dextromethorphan and bupropion) Extended-Release Tablets</i> • <i>Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) Inhalation Aerosol</i> • <i>Dupixent (dupilumab) Injection</i> • <i>Stelara (ustekinumab) Injection</i> <i>The following medications were reviewed and will be kept as Non-formulary. Prior Authorization criteria will be developed as needed:</i> • <i>Gwyn Lo (ethinyl estradiol and norelgestromin) Transdermal System*</i> • <i>Garzulys (insulin aspart-fsan) Injection*</i> • <i>Lytenava (bevacizumab-vikg) Intravitreal Injection - formerly ONS-5010*</i> • <i>Simtriyo (centanafadine) Extended-Release Capsules*</i> • <i>Tylenol with Naproxen (acetaminophen and naproxen sodium) Tablets*</i> • <i>Furoscix (furosemide) Injection</i> • <i>Fabhalta (iptacopan) Capsules</i> • <i>Lipfendra (enlicitide) Tablets*</i> • <i>Legembi (lecanemab-irmb) Injection</i> • <i>Ryaltris (mometasone furoate and olopatadine hydrochloride) Nasal Spray</i> • <i>Trutakna (atacept-vymj) Injection*</i> • <i>Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) Injection</i>	<i>provided if this timeframe is not met. Formularies must include substantially all drugs in the six protected categories that are FDA approved by the last CMS specified HPMS formulary upload date for the upcoming contract year. New drugs or newly approved uses for drugs within the six classes that come onto the market after the CMS specified formulary upload date will be subject to an expedited P&T committee review. The expedited review process requires P&T committees to make a decision within 90 days, rather than the normal 180-day requirement. At the end of the 90 day period, these drugs must be added to Part D plan formularies.” (See attached for voting detail.)</i>			
--	---	--	--	--	--

	• <i>Casgevvy (exagamglogene autotemcel) Suspension for Intravenous Infusion</i> • <i>Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) Formerly Orca-T*</i> • <i>Zoryve (roflumilast) Cream and Foam</i> • <i>Lumvoa (veligrotug-vvze) Injection*</i> • <i>Tryngolza (olezarsen) Injection</i> • <i>Utebzi (tebipenem pivoxil) Tablets*</i> • <i>Rextovy (naloxone hydrochloride) Nasal Spray</i> • <i>Tzield (teplizumab-mzwv) Injection</i> • <i>Ambelvist (gadoquatrane) Injection*</i> • <i>Ebglyss (lebrikizumab-lbkz) Injection</i> • <i>Hympavzi (marstacimab-hncq) Injection</i> • <i>Ranluspec (ranibizumab-hkdz) Intravitreal Injection*</i> • <i>Xocova (ensitrelvir) Tablets*</i> • <i>Zaynich (cefepime and zidebactam) Powder for Injection*</i> • <i>Cypsedo (cipepofol) Injection*</i> • <i>Afrezza (insulin human [rDNA origin]) Inhalation Powder</i> • <i>Hepcludex (bulevirtide-gmod) Lyophilized Powder for Injection*</i> • <i>Differin Epiduo Acne Gel (adapalene and benzoyl peroxide) Topical Gel*</i> • <i>Tofidence (tocilizumab-bavi) Injection</i> • <i>Baxfendy (baxdrostat) Tablets*</i> • <i>Immgolis (golimumab-sldi) Injection*</i> • <i>Trimbow (beclomethasone dipropionate, formoterol fumarate and glycopyrrolate) Inhalation Aerosol*</i> • <i>Ocrevus (ocrelizumab) Injection</i> • <i>Vyvgart (efgartigimod alfa-fcab) Injection</i> • <i>Ennumo (pegfilgrastim-pccg) Injection*</i> • <i>Asceniv (immune globulin intravenous, human – slra) Injection</i> • <i>Langlara (insulin glargine-aldy) Injection*</i> • <i>Saphnelo (anifrolumab-fnia) Injection</i> • <i>Crysvida (burosumab-twza) Injection</i> • <i>Otarmeni (lunsotogene parvec-cwha) Suspension for Intracochlear Infusion*</i> • <i>Filspari (sparsentan) Tablets</i> • <i>Vabysmo (faricimab-svoa) Intravitreal Injection</i> (*Drug also included in the New Drug Review for Medicaid)				
--	--	--	--	--	--

VI. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held October 2026.

A handwritten signature in blue ink that reads "Danielle Dolores". The signature is written in a cursive style with a large initial 'D'.

9/2/2026

Danielle Dolores, Director of Pharmacy Services

Date

APPENDIX I: VOTING GRID

	Danielle Dolores, PharmD	George Downs, PharmD	Lawrence Jones, RPh	Tania Kolev, MD	Hannah McCaffrey	Sanjiv Raj	Kaylei Koervitz	Heather Scheckner	Merleen Harris-Williams, MD	Demian Elder, MD	Edgar Chou, MD	Comments
<i>Minutes Review/Approval</i>	A	A	A	A	A	E	A	A	E	E	A	<i>May 2026</i>
<i>2027 Prior Authorization Criteria – CMS Review</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Step Therapy Criteria CMS Review</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Formulary Additions – CMS Review</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Formulary Additions – Summer Limited Window</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Formulary Removals</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Quantity Limit Updates</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Tier Changes – CMS Review</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2027 Quantity Limit Additions</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2026 Prior Authorization Criteria Updates</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2026 Formulary Additions</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2026 FRF Formulary Additions - Protected Class</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2026 FRF Formulary Additions – Non-Protected Class</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2026 FRF Formulary Removals</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>2026 Quantity Limit Additions</i>	A	A	A	A	A	E	A	A	E	E	A	
<i>New Drug Review</i>	A	A	A	A	A	E	A	A	E	E	A	

*A = Approved as presented * R = Rejected * E = Excused from meeting * P = Precluded from vote due to conflict of interest